Medscheme Seeks High Court Intervention in Bonitas Tender Dispute

Key Takeaways

• Medscheme Holdings has launched a high court application to stop Bonitas Medical Scheme from proceeding with its tender for administration and managed care services.
• The application seeks an interim interdict suspending Bonitas’ current tender process pending the outcome of a forensic investigation by the Council for Medical Schemes.
• The dispute involves allegations of a compromised tender process, with Medscheme arguing that the integrity and legitimacy of the process have been compromised.
• The Council for Medical Schemes has launched a forensic investigation into Bonitas, which is ongoing.
• The outcome of the court application could have significant implications for the medical schemes industry, including the potential for disruption to member benefits and access to care.

Introduction to the Dispute
Medscheme Holdings has launched an urgent high court application to stop Bonitas Medical Scheme from proceeding with its tender for administration and managed care services. The application, filed on Monday, 15 December 2025, seeks an interim interdict suspending Bonitas’ current tender process pending the outcome of a forensic investigation by the Council for Medical Schemes. The matter is set down for hearing on 3 March 2026. At stake is the administration of South Africa’s second-largest open medical scheme, with roughly one million beneficiaries, and annual contributions of about R20-billion.

The Tender Process
Medscheme’s application targets two requests for proposals issued by Bonitas in July 2025, covering administration services and managed care. In court documents, Medscheme argues that the integrity and legitimacy of the tender process have been compromised, asserting that it is the "antithesis of a fair, equitable, transparent and bona fide process". Medscheme, Bonitas’ incumbent service provider for administration and managed care since 1982, fears that proceeding with an award would cause irreparable harm to the scheme, its members, and other bidders.

Forensic Investigation
The legal challenge comes at a time when the company is already under the microscope. In November 2025, the Council for Medical Schemes confirmed it had escalated an inquiry into Bonitas to a full forensic investigation under Section 44 of the Medical Schemes Act. Medscheme’s application draws on allegations from a column by BusinessDay journalist Michael Avery, which purportedly exposed a concerted effort by internal executives and external associates to capture the scheme. The Council for Medical Schemes has resolved to initiate a forensic investigation to examine the full scope of the claims and to formulate appropriate recommendations.

Allegations of a Compromised Process
The allegedly corrupt tender processes at Bonitas involve the steering of marketing and distribution contracts to associated entities by manipulating bidding rules. Medscheme wants to halt current tenders due to concerns that the entire process is "fatally and inherently flawed". The capture allegedly began with a board-approved strategy called "Project StepAhead", which was purportedly either copied or branded from proprietary information belonging to the incumbent service provider, AfroCentric Distribution Services (ADS). The coordination of this strategy involved Bonitas principal officer Lee Callakoppen, consultant Tobie du Preez, former AfroCentric executive Willem Britz, and Bonitas scheme attorney Aneesa Mahomed.

Current Compromised Tender
The urgent court application also relies on evidence suggesting the current tender process for administration and managed care services is also compromised. A central piece of evidence highlighted in the court documents is a bank confirmation letter dated 31 July 2025, confirming that WHB Holdings (a Britz-related entity) committed R150-million to Private Health Administrators should it win the remaining managed care and administration services contracts. Private Health Administrators, which already manages Bonitas’ low-cost BonCap option, is listed as the third respondent in Medscheme’s interdict and is an active contender in the current requests for proposals process.

Bonitas’ Response
Bonitas has rejected Medscheme’s calls to suspend the tender process. In correspondence from its attorneys, the scheme argues that Medscheme, as an incumbent service provider and competing bidder, has no right to dictate its procurement decisions or demand access to internal information. Bonitas asserted that Medscheme’s action was aimed at "derail[ing] the legitimate ongoing request for proposals processes to enable it to remain indefinitely in its aforesaid positions". Bonitas further explicitly denied any allegations of irregularity and questioned the motives behind Medscheme’s allegations.

Risks of Disruption
Medscheme’s urgency is driven by timing. According to its court papers, contract awards are expected in mid-December 2025, with implementation scheduled for 1 June 2026. As the second-largest medical scheme in South Africa, covering approximately one million beneficiaries, an administrative change for Bonitas is described in court documents as a "Herculean task" typically requiring six to 12 months for completion. Medscheme contends that proceeding with the award under the shadow of the Council for Medical Schemes probe creates a risk of temporary instability within the scheme, threatening disruptions to member benefits, access to care, chronic medication supply, and overall scheme reputation should the probe reveal serious wrongdoing warranting curatorship or the invalidation of the contracts.

Conclusion
The high court will now be asked to decide whether the tender should be frozen until the Council for Medical Schemes completes its work, an interim ruling that could determine Bonitas’ future and confidence in governance across the medical schemes industry. The outcome of the court application will have significant implications for the medical schemes industry, including the potential for disruption to member benefits and access to care. The case highlights the importance of ensuring the integrity and legitimacy of tender processes, particularly in the medical schemes industry where the stakes are high and the potential for harm to beneficiaries is significant.